{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04947501",
            "orgStudyIdInfo": {
                "id": "21-228"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "A Study of N9 Chemotherapy in Children With Neuroblastoma",
            "officialTitle": "N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-of-chemotherapy-in-children-with-neuroblastoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-06-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-22",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-22",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-06-23",
            "studyFirstSubmitQcDate": "2021-06-23",
            "studyFirstPostDateStruct": {
                "date": "2021-07-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times - Cyclophosphamide, topotecan, and vincristine (CTV), Ifosfamide, carboplatin, and etoposide (ICE), Cyclophosphamide, doxorubicin, and vincristine (CDV)."
        },
        "conditionsModule": {
            "conditions": [
                "Neuroblastoma",
                "Pediatric Cancer"
            ],
            "keywords": [
                "HR-NB",
                "Neuroblastoma",
                "pediatric cancer",
                "21-228",
                "Memorial Sloan Cancer Center"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants with newly-diagnosed HR-Neuroblastoma",
                    "type": "EXPERIMENTAL",
                    "description": "This pilot study of N9 as induction chemotherapy will enroll 30 patients with newly-diagnosed HR-NB. A first cohort of \\>1 to 12-year old, and a second cohort of extended age \\<19 years old. Both cohorts will be analyzed together.",
                    "interventionNames": [
                        "Drug: Cyclophosphamide",
                        "Drug: Topotecan",
                        "Drug: Vincristine",
                        "Drug: Doxorubicin",
                        "Drug: Ifosfamide",
                        "Drug: Etoposide",
                        "Drug: Carboplatin",
                        "Drug: Mesna"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Administration of CTV - cycles 1 and 4\n\nDays 1 \\& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \\>10 years old), IV over 6 hrs.\n\nMesna 70 mg/kg (2100 mg/m2/day for patients \\>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.\n\nDays 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.\n\n\\*\\*\\*\\*\\*\\*\\* Administration of CDV - cycle 3 Days 1 \\& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \\>10 years old), IV over 6 hrs.\n\nMesna 70 mg/kg ((2100 mg/m2/day for patients \\>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.\n\nDays 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).\n\nDays 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.",
                    "armGroupLabels": [
                        "Participants with newly-diagnosed HR-Neuroblastoma"
                    ],
                    "otherNames": [
                        "Cytoxan"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Topotecan",
                    "description": "Administration of CTV - cycles 1 and 4\n\nDays 1 \\& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \\>10 years old), IV over 6 hrs.\n\nMesna 70 mg/kg (2100 mg/m2/day for patients \\>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.\n\nDays 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.",
                    "armGroupLabels": [
                        "Participants with newly-diagnosed HR-Neuroblastoma"
                    ],
                    "otherNames": [
                        "Hycamtin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Vincristine",
                    "description": "Administration of CTV - cycles 1 and 4\n\nDays 1 \\& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \\>10 years old), IV over 6 hrs.\n\nMesna 70 mg/kg (2100 mg/m2/day for patients \\>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.\n\nDays 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.",
                    "armGroupLabels": [
                        "Participants with newly-diagnosed HR-Neuroblastoma"
                    ],
                    "otherNames": [
                        "Oncovin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Doxorubicin",
                    "description": "Administration of CDV - cycle 3 Days 1 \\& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \\>10 years old), IV over 6 hrs.\n\nMesna 70 mg/kg ((2100 mg/m2/day for patients \\>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.\n\nDays 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).\n\nDays 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr.",
                    "armGroupLabels": [
                        "Participants with newly-diagnosed HR-Neuroblastoma"
                    ],
                    "otherNames": [
                        "Adriamycin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ifosfamide",
                    "description": "Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \\<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \\<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \\<10 kg), IV over 2 hrs.",
                    "armGroupLabels": [
                        "Participants with newly-diagnosed HR-Neuroblastoma"
                    ],
                    "otherNames": [
                        "Isophosphamide"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Etoposide",
                    "description": "Administration of ICE - cycle 2\n\nDays 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \\<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \\<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \\<10 kg), IV over 2 hrs.",
                    "armGroupLabels": [
                        "Participants with newly-diagnosed HR-Neuroblastoma"
                    ],
                    "otherNames": [
                        "VePesid",
                        "Etopophos"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "Administration of ICE - cycle 2\n\nDays 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \\<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \\<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \\<10 kg), IV over 2 hrs.",
                    "armGroupLabels": [
                        "Participants with newly-diagnosed HR-Neuroblastoma"
                    ],
                    "otherNames": [
                        "Paraplatin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Mesna",
                    "description": "Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients \\>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.\n\nAdministration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.\n\nAdministration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients \\>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.",
                    "armGroupLabels": [
                        "Participants with newly-diagnosed HR-Neuroblastoma"
                    ],
                    "otherNames": [
                        "Mesnex"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Assess safety of the N9 regimen in participants with HR-NB through toxicity assessment",
                    "description": "Adverse events will be graded using Common Toxicity Criteria Version 5.0 developed by the National Cancer Institute of the USA, events of all grades will be tabulated, for non-hematologic effects and hematologic effects on the patients in the safety set. The timing of cycles will also be described to assess any delay due to toxicity",
                    "timeFrame": "16 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of NB as defined by histopathology (confirmed by the MSK Department of Pathology), BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.\n* HR-NB, defined as MYCN-amplified stage 2/3/4/4S at any age and stage 4 in patients \\>18 months old.\n* No more than one prior cycle of chemotherapy.\n* Age \\<19 years old.\n* Signed informed consent indicating awareness of the investigational nature of this treatment.\n\nExclusion Criteria:\n\n* Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity \u2265 grade 3.\n* Inability to comply with protocol requirements.\n* Pregnancy is not an issue because all patients will be pre-adolescents.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "1 Year",
            "maximumAge": "19 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Brian Kushner, MD",
                    "role": "CONTACT",
                    "phone": "1-833-MSK-KIDS",
                    "email": "kushnerb@MSKCC.ORG"
                },
                {
                    "name": "Shakeel Modak, MD",
                    "role": "CONTACT",
                    "phone": "1-833-MSK-KIDS"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Brian Kushner, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brian Kushner, MD",
                            "role": "CONTACT",
                            "phone": "833-675-5491"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009447",
                    "term": "Neuroblastoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018241",
                    "term": "Neuroectodermal Tumors, Primitive, Peripheral"
                },
                {
                    "id": "D000018242",
                    "term": "Neuroectodermal Tumors, Primitive"
                },
                {
                    "id": "D000018302",
                    "term": "Neoplasms, Neuroepithelial"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12391",
                    "name": "Neuroblastoma",
                    "asFound": "Neuroblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20387",
                    "name": "Neuroectodermal Tumors, Primitive, Peripheral",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M20446",
                    "name": "Neoplasms, Neuroepithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T4085",
                    "name": "Neuroblastoma",
                    "asFound": "Neuroblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000007069",
                    "term": "Ifosfamide"
                },
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "D000004317",
                    "term": "Doxorubicin"
                },
                {
                    "id": "D000005047",
                    "term": "Etoposide"
                },
                {
                    "id": "D000014750",
                    "term": "Vincristine"
                },
                {
                    "id": "D000019772",
                    "term": "Topotecan"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000059004",
                    "term": "Topoisomerase I Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8191",
                    "name": "Etoposide",
                    "asFound": "Complete",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10117",
                    "name": "Ifosfamide",
                    "asFound": "Ventricular",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7492",
                    "name": "Doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17495",
                    "name": "Vincristine",
                    "asFound": "Phase I",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21674",
                    "name": "Topotecan",
                    "asFound": "Staff",
                    "relevance": "HIGH"
                },
                {
                    "id": "M227339",
                    "name": "Liposomal doxorubicin",
                    "relevance": "LOW"
                },
                {
                    "id": "M341643",
                    "name": "Etoposide phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M230811",
                    "name": "Isophosphamide mustard",
                    "relevance": "LOW"
                },
                {
                    "id": "M17811",
                    "name": "Mesna",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M29349",
                    "name": "Topoisomerase I Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}